Cargando…
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
BACKGROUND: Recent clinical studies have revealed that sodium glucose co-transporter 2 inhibitors (SGLT2i) reduced cardiovascular events in type 2 diabetes. Here, we investigated whether empagliflozin, as a kind of SGLT2i, could alleviate atherosclerosis progression in non-diabetic mice. METHODS: Ap...
Autores principales: | Liu, Yihai, Wu, Mingyue, Xu, Biao, Kang, Lina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8180283/ https://www.ncbi.nlm.nih.gov/pubmed/34103961 http://dx.doi.org/10.2147/JIR.S309427 |
Ejemplares similares
-
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
por: Liu, Yihai, et al.
Publicado: (2021) -
M2-like macrophages transplantation protects against the doxorubicin-induced heart failure via mitochondrial transfer
por: Liu, Yihai, et al.
Publicado: (2022) -
Myeloid-derived growth factor inhibits inflammation and alleviates endothelial injury and atherosclerosis in mice
por: Meng, Biying, et al.
Publicado: (2021) -
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
por: Lee, Seul-Gee, et al.
Publicado: (2020) -
Aqueous Extract of Nypa fruticans Wurmb. Vinegar Alleviates Postprandial Hyperglycemia in Normoglycemic Rats †
por: Yusoff, Nor Adlin, et al.
Publicado: (2015)